Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Regulatory News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

5 Jun 2009 17:15

RNS Number : 4872T
Skyepharma PLC
05 June 2009
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

SkyePharma Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

Delta adjustment

X

3. Full name of person(s) subject to the notification obligation: iii

D. E. Shaw & Co., L.P. 

D. E. Shaw & Co. (U.K.), Ltd. 

4. Full name of shareholder(s)  (if different from 3.):iv

N/A

5. Date of the transaction and date on which the threshold is crossed or reached: v

June 3, 2009

6. Date on which issuer notified:

June 5, 2009

7. Threshold(s) that is/are crossed or reached: vi, vii

35%

  

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/  Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Contract for Differences ("CfD") relating to convertible bond due 2024

March 4, 2010

3,223,697

Nominal

Delta

13.85%

CfD relating to convertible bond due 2025

November 30, 2009

2,506,326

Nominal

Delta

10.77%

CfD relating to convertible bond due 2025

June 3, 2010

2,506,326

Nominal

Delta

10.77%

Total (A+B+C)

Number of voting rights

Percentage of voting rights

8,236,349

35.40%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Each of D. E. Shaw & Co., L.P. ("DESCO LP") and D. E. Shaw & Co. (U.K.), Ltd. ("DESCO UK") is notifying solely in its capacity as a discretionary investment manager. As general partner of DESCO LP, D. E. Shaw & Co., Inc. ("DESCO Inc.") is a parent undertaking of DESCO LP and DESCO UK. By virtue of David E. Shaw's position as president and sole shareholder of DESCO, Inc., which is the general partner of DESCO LP, David E. Shaw is a parent undertaking of DESCO LP and DESCO UK.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Stephen Back (Compliance Department)

15. Contact telephone number:

+1 212-478-0000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLQELFBKQBFBBL
Date   Source Headline
19th Jan 20105:40 pmRNSHolding(s) in Company
18th Jan 20105:23 pmRNSHolding(s) in Company
13th Jan 20106:17 pmRNSHolding(s) in Company
12th Jan 20105:58 pmRNSHolding(s) in Company
6th Jan 20105:22 pmRNSHolding(s) in Company
5th Jan 20106:11 pmRNSHolding(s) in Company
4th Jan 201011:23 amRNSDirectorate Change
22nd Dec 20094:56 pmRNSShare Purchase Plan
1st Dec 200910:57 amRNSShare Purchase Plan
18th Nov 20097:00 amRNSBoard Change
12th Nov 20097:00 amRNSInterim Management Statement
3rd Nov 20095:13 pmRNSShare Purchase Plan
2nd Nov 200910:07 amRNSFlutiform EU Clinical Trial Successfully Completed
1st Oct 20091:21 pmRNSShare Purchase Plan
8th Sep 20092:09 pmRNSHolding(s) in Company
1st Sep 200910:09 amRNSShare Purchase Plan
1st Sep 20097:00 amRNSResearch Update
21st Aug 20097:00 amRNSHalf Yearly Report
3rd Aug 20092:13 pmRNSShare Purchase Plan
24th Jul 20093:56 pmRNSHolding(s) in Company
24th Jul 200911:01 amRNSHolding(s) in Company
20th Jul 200911:48 amRNSHolding(s) in Company
17th Jul 20097:00 amRNSRe Agreement
14th Jul 200911:08 amRNSHolding(s) in Company
10th Jul 20095:10 pmRNSHolding(s) in Company
9th Jul 20095:35 pmRNSHolding(s) in Company
1st Jul 20093:57 pmRNSDirector Declaration
30th Jun 20093:42 pmRNSShare Purchase Plan
30th Jun 200911:35 amRNSTotal Voting Rights
26th Jun 20096:09 pmRNSHolding(s) in Company
24th Jun 20094:59 pmRNSHolding(s) in Company
23rd Jun 20093:42 pmRNSHolding(s) in Company
22nd Jun 20094:15 pmRNSHolding(s) in Company
22nd Jun 20093:23 pmRNSConversion of Bonds
17th Jun 20095:43 pmRNSHolding(s) in Company
17th Jun 20094:44 pmRNSHolding(s) in Company
11th Jun 20095:09 pmRNSHolding(s) in Company
10th Jun 20095:30 pmRNSHolding(s) in Company
9th Jun 20095:18 pmRNSHolding(s) in Company
9th Jun 20093:00 pmRNSResearch Update
5th Jun 20096:16 pmRNSHolding(s) in Company
5th Jun 20095:15 pmRNSHolding(s) in Company
5th Jun 200910:36 amRNSHolding(s) in Company
4th Jun 20096:26 pmRNSHolding(s) in Company
3rd Jun 20094:46 pmRNSDirector/PDMR Shareholding
29th May 20096:20 pmRNSShare Purchase Plan
29th May 200911:37 amRNSTotal Voting Rights
28th May 20093:34 pmRNSHolding(s) in Company
27th May 20091:55 pmRNSReplacement: Conversion of ?50,000 6% 2024 Bonds
22nd May 20097:00 amRNSFlutiform NDA Accepted for Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.